Last year, when I participated in a Transparency International delegation in Washington DC and New York, a number of formal meetings and informal chats were circulating around the idea that Viktor Orban's 'illiberalism' – well, to put it more correctly: hybrid regime or autocracy – could be built in the US. Seeing Donald Trump's... More detail

Will post-Brexit Britain be a beacon or buccaneer on financial crime?

Today marks the third anniversary of the 2016 Anti-Corruption Summit, at which the UK committed to a number of ambitious new initiatives to fight corruption both in this country and around the world. Although many of the UK’s commitments have been implemented, some key pledges are now long overdue. These notably include a commitment... More detail

Business and the UK's Anti-Corruption Strategy - bear-traps and opportunities

Robert Barrington. Executive Director of Transparency International UK, reflects on the opportunities and challenges for the UK Government in engaging the business community over the national Anti-Corruption Strategy.
As part of its widely-acclaimed national Anti-Corruption Strategy, the UK Government aims to engage the business community. There is good reason to do so. Businesses can be... More detail

Reflections on a decade in the fight against corruption and the coming challenges

After eleven years at Transparency International UK, Robert Barrington will be moving on from his post as Executive Director to take up a role as Professor of Anti-Corruption Practice in September. Here he reflects on some of the successes he has seen over the past decade, and future challenges for the anti-corruption movement.
When I... More detail

Here’s why we need Suspicious Minds in order to go on together

The following is a guest post from Adam Williamson - Head of Professional Standards at AAT (Association of Accounting Technicians)
Money laundering is big business. The National Crime Agency estimates that money laundering helps enable serious and organised crime that costs the UK an estimated £37 billion each year. This rises to hundreds of billions... More detail

In February 2014 the UK media claimed that NHS England had, despite prior knowledge, invited a patients group entirely funded by the pharmaceutical industry and headed by a well-known pharmaceutical industry lobbyist to draft a report which could affect future NHS policy. The group is called the Specialised Healthcare Alliance and its Director, John Murray, also heads a lobbying firm whose clients include some of the world’s biggest drug and medical device firms.